Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial

BACKGROUND: Impulse control disorders (ICDs) are frequently encountered in Parkinson’s disease (PD). OBJECTIVES: We aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs. METHODS: We conducted a multicentre trial in five movement disorder departments. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurencin, Chloé, Timestit, Noémie, Marques, Ana, Duchez, Domitille Dilly, Giordana, Caroline, Meoni, Sara, Huddlestone, Marine, Danaila, Teodor, Anheim, Mathieu, Klinger, Hélène, Vidal, Tiphaine, Fatisson, Marion, Caire, Catherine, Nourredine, Mikail, Boulinguez, Philippe, Dhelens, Carole, Ballanger, Bénédicte, Prange, Stéphane, Bin, Sylvie, Thobois, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511565/
https://www.ncbi.nlm.nih.gov/pubmed/37338615
http://dx.doi.org/10.1007/s00415-023-11814-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511565/
https://www.ncbi.nlm.nih.gov/pubmed/37338615
http://dx.doi.org/10.1007/s00415-023-11814-y

Ejemplares similares